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Abstract 
Study Objective: To examine the impact of multiple risk alleles for cognitive dysfunction and 
cardiovascular disease risk on cognitive function, and to determine if these relationships varied 
by cognitive reserve (CR) or concomitant medication use in patients with schizophrenia. 
Design: Cross-sectional study. 
Setting: Ambulatory mental health centers. 
Patients: A total of 122 adults with a schizophrenia spectrum diagnosis who were maintained 
on a stable antipsychotic regimen for at least 6 months prior to study enrollment; patients were 
divided into three CR groups based on years of formal education: no high school completion or 
equivalent (low-education group [18 patients]); completion of high school or equivalent 
(moderate-education group [36 patients]; or any degree of post–high school education (high-
education group [68 patients]). 
Measurements and Main Results: The following pharmacogenomic variants were genotyped 
for each patient: AGT M268T (rs699), ACE insertion/deletion (or ACE I/D, rs1799752), and 
APOE ε2, ε3, and ε4 (rs429358 and rs7412). Risk allele carrier status (identified per gene as 
AGT M268 T carriers, ACE D carriers, and APOE ε4 carriers) was not significantly different 
among CR groups. The Brief Assessment of Cognition in Schizophrenia (BACS) scale was used 
to assess cognitive function. The mean ± SD patient age was 43.9 ± 11.6 years. Cardiovascular 
risk factors such as hypertension and hyperlipidemia diagnoses, and use of antihypertensive 
and lipid-lowering agents, did not significantly differ among CR groups. Mixed modeling 
revealed that risk allele carrier status was significantly associated with lower verbal memory 
scores for ACE D and APOE ε4 carriers, but AGT T carrier status was significantly associated 
with higher verbal memory scores (p=0.0188, p=0.0055, and p=0.0058, respectively). These 
results were only significant in the low-education group. Additionally, medication-gene 
interactions were not significant predictors of BACS scores. 
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Conclusion: ACE D and APOE ε4 carrier status, independent of medication use, was 
associated with lower verbal memory scores in patients with schizophrenia who had relatively 
lower CR, as identified by formal education. These results suggest that increasing CR may be 
protective against cognitive impairment that may be worsened by select cardiovascular risk 
alleles in patients with schizophrenia. 
 
 
 
 
Evidence supporting a connection between cardiovascular disease and cognitive dysfunction 
has received increasing attention and support in recent research.1,2 Patients with schizophrenia 
have the potential to be severely impacted by this association due to high rates of comorbid 
cardiovascular disease and varying degrees of baseline cognitive dysfunction. In fact, cognitive 
dysfunction is considered a core feature of schizophrenia that is usually observable prior to the 
first episode of psychosis, often persists through treatment,3,4 and contributes significantly to an 
individual’s decreased functional capacity5 and quality of life.6 Few investigations have 
attempted to understand how factors that impact cardiovascular function and cognition, such as 
medication use, pharmacogenomics, and cognitive reserve (CR), moderate cognitive 
dysfunction in patients with schizophrenia. Our group was one of the first to report a relationship 
between cardiovascular health and neurocognition in patients with schizophrenia.7
 
 
Understanding the extent of this complex relationship has potential to improve treatment 
outcomes in patients with schizophrenia.   
A number of pharmacogenomic variants exist with potential to moderate cardiovascular health 
and cognitive function.  These include single nucleotide polymorphisms (SNPs) within the renin-
angiotensin system (RAS), which is essential to blood pressure maintenance, as well as 
apolipoprotein E, which has been implicated in the risk for Alzheimer’s disease and 
dyslipidemia. Three variants impacting these systems were chosen for analysis based on study 
results in the general adult population that support their potential to impact cardiovascular health 
and cognition.8–10
 
  
AGT M268T 
Increased RAS activity and blood pressure elevation have been linked to cognitive impairment 
and Alzheimer’s disease risk.11,12 Genetic variability contributes to RAS activity, and one such 
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variant is contained within the gene coding for the angiotensinogen (AGT) polypeptide. This 
missense mutation (referred to as AGT M268T or AGT M235T) leads to an amino acid change 
in the polypeptide from valine to threonine at amino acid position 268, and the threonine variant 
has been associated with increased angiotensin II concentrations.13 A recent study identified a 
pharmacogenetic relationship between cognitive decline, genotype, and RAS-active 
medication.8 Specifically, individuals homozygous for the threonine allele who also used an 
angiotensin-converting enzyme inhibitor (ACEI) showed significantly less cognitive decline than 
other genotypes after 8 years of follow-up.8
 
 Currently, to our knowledge, there are no published 
studies that have examined the relationship between this variant, medication use, and cognition 
in patients with schizophrenia. 
ACE I/D 
The ACE is important in the RAS pathway because it is responsible for the production of 
angiotensin II, which is the effector molecule ultimately leading to increased blood pressure.15 A 
common polymorphism in the gene coding for this enzyme is an insertion/deletion (I/D) variant. 
Carriers of the D allele produce more ACE16 and have been shown to be at risk for higher rates 
of adverse cardiovascular outcomes.17 A study by in elderly patients (aged 59-71 years) found 
that scores on the Mini-Mental State Examination declined significantly more after a 4-year 
follow-up in DD allele carriers compared with ID allele carriers.18 Further, in elderly individuals 
(mean ± SD age 64 ± 8.08 years), carriers of the I allele had higher verbal memory scores 
compared with DD carriers, but the benefit of the I allele was present only in subjects using ACE 
inhibitors when assessing learning ability.9 This variant has also been associated with significant 
changes in white matter that correlated D carrier status with both positive and negative impact 
on cognition.19 Like AGT M268T, the relationship between this allele, medication use, and 
cognitive function in patients with schizophrenia has not been well studied, although several 
investigators have looked at the relationship between this polymorphism, or levels of ACE 
activity, and schizophrenia incidence.20,21
 
  
APOE 
Apolipoprotein E (APOE) is a plasma lipoprotein involved in synaptic signaling and plasticity, as 
well as transporting lipids throughout the blood stream.22 The most studied APOE variants (ε2, ε3, and ε4) are based on rs429358 and rs7412 SNP combinations.23 APOE ε4 has been 
associated with an increased risk for, and earlier onset of, Alzheimer’s disease, cognitive 
dysfunction in nondemented older adults, and dyslipidemias.24–26 Although the mechanism for 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
6 
this allele’s effect on cognition is not fully understood, some have hypothesized adverse 
changes in APOE’s neuroprotective and neurotoxic profile.22 Among those with serious mental 
illness, results regarding the relationship between the ε4 allele and cognitive dysfunction have 
been somewhat conflicting. In patients with bipolar disorder, worsening cognitive function across 
several domains has been associated with ε4 carrier status, but this finding has not been 
replicated consistently in patients with schizophrenia.27,28 With respect to cardiovascular 
parameters that have been linked to worsened cognition, APOE ε4 carrier status has been 
related to increased total cholesterol level in patients with schizophrenia taking atypical 
antipsychotics, and in the general population response to statins has been associated with 
APOE status.10,29
 
 However, a robust association between statin use, APOE ε4 status, and 
cognition has not been demonstrated.  
Although the role of these pharmacogenomic variants in schizophrenia has yet to be thoroughly 
examined, we also recognize that a patient’s CR may play an important role in the complex 
relationship between pharmacogenetic variability, cardiovascular health, and cognitive function. 
A core concept of CR is that select environmental experiences are protective against cognitive 
decline in disease states such as Alzheimer’s disease, dementia, schizophrenia, and multiple 
sclerosis.30–32 CR was originally postulated following observations in patients with Alzheimer’s 
disease in whom clinical status deteriorated less than would be expected based on changes in 
brain physiology.33,34 Additional work has since associated CR characteristics such as degree of 
formal education, premorbid IQ, and physical activity with a phenotype of higher cognitive 
function than expected based on underlying diagnosis.35,36 Studies attempting to identify valid 
measures of CR in patients with schizophrenia have recognized factors such as educational 
level, premorbid IQ, and physical activity, as possible proxy measures for CR.32,37
 
 However, at 
this time there is no single established proxy measure for classifying degree of CR in any of the 
aforementioned disease states. 
Investigations studying the relationship between cognitive function, pharmacogenomic variants 
in cardiovascular health, and the importance of CR in patients with schizophrenia treated with 
antipsychotics are lacking. Therefore, the aim of this study was to examine the impact of 
multiple risk alleles for cognitive dysfunction and cardiovascular disease risk on the Brief 
Assessment of Cognition in Schizophrenia (BACS) scale performance, and to determine if these 
relationships varied by CR or concomitant medication use in patients with schizophrenia. To 
identify variable relationships between BACS scores and CR, patients were divided into three 
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groups based on their degree of formal education. We hypothesized that the select risk alleles 
would be significant independent variables in the predication of BACS scores and that these 
relationships would vary between CR groups and be moderated by ACEI, angiotensin II 
receptor blocker (ARB), or statin medication use. 
 
Methods 
Study Design and Patients 
All patients included in this cross-sectional study were part of an ongoing larger study 
investigating pharmacogenetic predictors of cardiovascular disease risk in patients with 
schizophrenia, as related to antipsychotic use.  To be included in this study, patients had to be 
diagnosed with schizophrenia, schizoaffective disorder, or psychotic disorder not otherwise 
specified.  All patients were required to be taking an antipsychotic for at least 6 months prior to 
study enrollment, and only adults were included (18-90 years of age). When possible, 
medication history was verified by referencing electronic charts and reviewing prescription 
records. Exclusion criteria included inability to give informed consent, currently pregnant or 
nursing, or an active substance abuse disorder. Full inclusion and exclusion criteria are 
available at https://clinicaltrials.gov/ct2/show/NCT00815854. The study protocol was approved 
by the following organizations: University of Michigan Medical School Institutional Review 
Board, Washtenaw County Health Organization, Ann Arbor Veterans Affairs Medical Center, 
and Detroit–Wayne County Community Mental Health Agency.  
 
Diagnostic, Clinical, and Demographic Assessments 
The Michigan Clinical Research Unit at the University of Michigan Medical Center housed all 
study visits. Following informed consent, patients underwent a fasting blood draw that included 
a blood sample for DNA extraction. Blood pressure, heart rate, medication history, and daily 
activity level were also obtained. Activity level was translated into a score using the Total 
Activity Measure 2, which has been validated against RT3 triaxial accelerometer measurements 
in a population with coronary heart disease.38 Diagnosis was verified using the Structured 
Clinical Interview for DSM-IV-TR Axis I Disorders (SCID).39 Education was assessed using 
SCID scoring that associates a numerical scale with education level on a range of 1 (completion 
of grade 6 or less) to 8 (completion of graduate/professional school).  Patients were divided into 
three CR groups according to their level of education: low, defined as incomplete high school or 
equivalent; moderate, defined as completed high school or equivalent; or high, defined as any 
post–high school education. 
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Cognitive Assessment 
The Brief Assessment of Cognition in Schizophrenia (BACS) scale was used to measure 
cognitive function. This scale focuses on assessing domains shown to be commonly impaired in 
schizophrenia: verbal memory, executive function, attention, verbal fluency, working memory, 
and motor speed.40
 
  
Genotyping 
DNA was extracted from whole blood using a salt precipitation method that has been described 
previously.41 All samples were genotyped for the following variants: ACE I/D (rs1799752), AGT 
M268T (rs699), and APOE (rs429358 and rs7412). For the AGT M268T variant, 
Pyrosequencing Technology (Qiagen, Valencia, CA) was used for assay design and creation of 
polymerase chain reaction (PCR) and sequencing primers. PCR was performed to amplify 
regions of interest prior to sequencing with a PyroMark MD sequencer, using Qiagen 
pyrosequencing reagents and following Pyrosequencing recommended protocols. (Primer 
sequences and PCR conditions are available by request.) The ACE I/D variant was assessed 
entirely by PCR, as previously described.42,43
 
 Two TaqMan assays (Thermo Fisher Scientific, 
Waltham, MA) were employed to assign APOE epsilon genotype based on results for variant 
rs429358 and rs7412. TaqMan Master Mix was used for the assay on LightCycler 480 real-time 
PCR equipment (Roche Molecular Diagnostics, Pleasanton, CA), with temperature and time 
settings recommended for the APOE TaqMan assay. Any uncertain genotype assignments were 
repeated for confirmation.  
Statistical Analysis 
JMP Pro 11.0 (2013) (SAS Institute Inc., Cary, NC) was used for all statistical analyses. 
Demographic data were analyzed by using one-way analysis of variance or χ2, as appropriate. 
Mixed modeling was used to predict BACS domain and cumulative scores for each CR group as 
a function of the following fixed effects: carriers of ACE D allele, AGT M268T threonine allele, 
APOE ε4 allele, and age. Race was kept as a random effect in the model to correct for 
significant differences between CR groups. Atypical antipsychotic use, interacting factors of 
ACEI or ARB use and RAS risk allele, and statin use and APOE ε4 carrier status, were not 
significant predictors in earlier model iterations and were removed to reduce the model 
parameters to only those significant fixed effects indicated above. Further mixed model analysis 
of recall ratio was undertaken on an exploratory basis with the final fixed and random effects. 
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Recall ratio, a derived assessment of verbal memory, was computed by dividing the number of 
words recalled (score) by the total possible number of words recalled in order to examine 
relative recall performance in addition to absolute recall performance. 
 
Results 
Patient Demographics and Genotypes 
A total of 122 patients were included in this study. Demographic characteristics are detailed in 
Table 1. Race was the only demographic characteristic that was significantly different among 
the three groups, with the high-education group having a greater percentage of Caucasian 
patients (p=0.04).  Rates of hypertension diagnosis, as well as use of an ACEI and ARB among 
groups were not significantly different (p=0.19 and p=0.92, respectively). Dyslipidemia diagnosis 
and statin use were also not significantly different among education groups (p>0.3 for all 
comparisons). Finally, the distribution of risk allele carrier status was also not significantly 
different among the three education groups (Table 2), and Hardy-Weinberg distribution did not 
significantly deviate from expected for the individual genetic variants (p>0.05, data not shown).  
 
Mixed Model Results 
Results of the mixed model analysis showed that verbal memory was the only BACS domain 
significantly influenced by select genotypes, and only in the low-education group; the estimates 
and probabilities for each fixed effect are shown in Table 3. The exploratory recall ratio 
performance analysis showed similar significant impact from genotypes, again in the low-
education group (Table 4). For both the verbal memory score and recall ratio, a higher score 
relative to the other patients with schizophrenia within the same education group equated to 
higher verbal memory capacity. As shown in Tables 3 and 4, all fixed effects parameter 
estimates influenced the predicted score negatively, with the exception of AGT risk allele carrier 
status. For example, in the verbal memory mixed model described in Table 3, APOE ε4 carrier 
status was associated with an approximate 6.4-point decrease in verbal memory score when all 
other variables were held constant using this prediction model. Medication use (ACEI or ARB 
interacted with RAS risk alleles, statin interacted with APOE ε4 carrier status, or atypical vs 
typical antipsychotic use) did not impact these results (data not shown). 
 
Discussion 
Our results suggest that in patients with schizophrenia, variants influencing ACE, APOE, and 
AGT activity may play an important role in determining cognitive function but primarily in those 
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who have relatively less CR, as indicated by lower formal education. The absence of a 
significant relationship between risk allele carrier status and BACS scores for patients with 
schizophrenia in the moderate- and high-education groups also suggests that it is possible for 
CR to protect against cognitive impairment that may be worsened by select cardiovascular risk 
alleles in patients with schizophrenia.  
 
In this population, medication use (atypical antipsychotic use, ACEI or ARB use interacted with 
RAS risk alleles, or statins interacted with APOE ε4 carrier status) did not moderate the 
relationship between ACE, APOE, and AGT and cognition. Previous pharmacogenomic 
research with the RAS risk alleles was primarily performed using ACEIs; however, it was felt 
important for this study to include ARBs as an interacting factor with RAS risk alleles because 
they also act directly on this system through angiotensin receptor blockade. Statins, but not 
other lipid-lowering agents, were included as an interacting term with APOE because literature 
supporting the pharmacogenomic impact of this risk allele has largely been related to statin use. 
These results were unexpected based on previously discussed literature suggesting that 
response to the selected risk alleles is significantly impacted by medication use.8–10 This is 
another area of research that deserves more attention due to the small number of patients in 
our low-education group, where significant impact of these risk alleles was detected. Finally, the 
lack of relationship between antipsychotic class (atypical vs typical antipsychotic use) and 
cognition has previously been described by our group and was included in our analysis due to a 
general lack of consensus on the complex relationship between antipsychotic class and 
cognition.7
 
  
The BACS cognitive domain that was significantly associated with risk alleles in this study was 
verbal memory—specifically, absolute and relative memory performance (i.e., total verbal 
memory and verbal memory recall ratio, respectively). Verbal memory is a complex cognitive 
domain that is well known for its moderate to severe impairment in schizophrenia.44 Our study 
suggests that verbal memory may be a sensitive measure for assessing the effects of multiple 
genetic variants on cognition in patients with schizophrenia with low CR, as the polymorphisms 
selected for this study impact cognition through a wide variety of mechanisms. Age was also a 
significant fixed parameter in both models, and this is in agreement with other studies that have 
shown increasing age to negatively influence cognitive function in patients with schizophrenia. 
45,46
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The positive relationship between AGT M268T threonine allele carrier status and total verbal 
memory and recall ratio scores warrants further investigation, as this allele would be expected 
to be associated with worsened, not improved, cognition. In our study this may be due to 
several factors, including the small sample size, average age, and possible race-specific effects. 
In a relatively large study by Hajjar et al, the relationship between this allele, ACEI use, and 
cognition varied by race, and among African-Americans, the relationship was not significant.8 
These results cannot be directly compared to our analysis but do suggest that we may be 
missing a race-specific effect due to our small sample size. Another factor that may be 
contributing to these unexpected results is the relatively young average age of our patients. In 
the limited number of previous trials that have investigated the association between the AGT 
M268T risk carrier status and cognition, studies have focused on older adults with average ages 
of 63–74 years.8,47 It is possible that the younger age of our patients is masking the impact of 
AGT M268T on cognition, as suggested by a number of studies showing an increased effect of 
genetics on cognition that correlates with advancing age.48
 
 
In our study, ACE D and APOE ε4 carrier status were associated with worsened verbal memory 
and recall ratio scores. These results support the rationale that excess angiotensinogen and 
APOE malfunction may worsen cognitive performance. With respect to the observed APOE ε4, 
relationship, these results contradict those described by Thiabut et al, where an association 
between worse cognitive scores and the presence of this risk allele was not found to be 
significant in small schizophrenic populations.28 This investigation compared the prevalence of 
the APOE ε4 risk allele in schizophrenic groups of varying cognitive abilities. As our analysis did 
not take the same approach, and our sample size is also small, this warrants further 
investigation. Furthermore, our results show a negative relationship between ACE D allele and 
cognition that has been supported in several studies.9,18
 
 
Finally, these results also suggest that increased CR, as identified by formal education, may 
temper the impact of genetic polymorphisms that place patients with schizophrenia at risk for 
cognitive dysfunction. A number of studies in cognitive remediation therapy also support the 
impact of educational programs after schizophrenia diagnosis in improving cognitive ability and 
functional outcome despite low CR.49  For example, Kontis et al found that patients with 
schizophrenia with “very low education” benefited significantly from cognitive remediation 
therapy and that older age was a more significant limiting factor in ability to benefit from 
therapy.49 A potentially important future clinical study would be to examine the impact of genetic 
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polymorphisms known to impact cognition on response to cognitive remediation therapy in a 
population of patients with schizophrenia with variable CR. It may prove to be the case that 
certain genetic risk factors for worsened cognitive function in patients with schizophrenia are 
clinically insignificant when patients receive cognitive remediation therapy. 
 
To the best of our knowledge, this is the first study to assess the impact of multiple 
cardiovascular polymorphisms on cognition in patients with schizophrenia with variable levels of 
CR. However, there are several limitations that must be addressed. One potential limitation is 
our measure of CR. Formal education has been linked to CR extensively in patients with 
Alzheimer’s disease, but it has been used less frequently in schizophrenia research.35 It is also 
possible that a more accurate proxy of CR could be established by incorporating multiple 
parameters associated with CR into a scoring system (such as education, IQ, and activity level), 
as suggested recently.37   Additionally, investigations in schizophrenia and CR caution that it 
may not be appropriate to simplify CR with premorbid indicators of cognitive capability in this 
population. For example, Leeson et al found that IQ following schizophrenia onset is a more 
reliable predictor of cognitive dysfunction and functional outcome in longitudinal studies when 
compared to IQ prior to schizophrenia onset.50
 
 Unfortunately, this information was not available 
for our current analysis. As IQ correlates with education, and other disease states have 
established educational attainment as a measure of CR, this suggests that our use of education 
as a premorbid indicator of CR in patients with schizophrenia should not be entirely discounted. 
Finally, there are two more obvious limitations of this study. One is the small number of patients, 
especially in the low-education group where the significant results with respect to genotype 
were identified. However, given the a priori prediction that genetic variants would have a 
differential impact on BACS score depending on education background, we proceeded with the 
analyses as planned to avoid increasing the possibility of type II error. The second additional 
limitation is that the potential significance of these results rest on the assumption that the 
selected fixed effects are linked by their potential to impact cardiovascular health and cognition. 
However, this is a developing area of study, and as these results are from a small, cross-
sectional investigation, they need to be interpreted with caution. 
 
Conclusion 
This study suggests that cognitive ability in patients with schizophrenia with relatively less CR 
may be moderated by risk alleles within the renin-angiotensin system (AGT M268T threonine 
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carriers and ACE I/D deletion carriers) and apolipoprotein E (APOE ε4 carriers). Interestingly, 
medications that have previously been shown to temper the impact of these risk alleles on 
cognition or cardiovascular parameters did not have significant impact in our population. This 
may be related to our small sample size and relatively young population, and warrants further 
attention. Future studies that evaluate the importance of cardiovascular pharmacogenomic 
variants, CR, and cognitive remediation therapy in patients with schizophrenia are needed to 
determine if these genetic variants and medication use are of clinical importance in improving 
quality of life in patients with schizophrenia receiving cognitive remediation therapy.  
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Characteristic 
All Patients 
(n=122) 
Low-Education Group 
(n=18) 
Moderate-Education 
Group 
(n=36) 
High-Education Group 
(n=68) 
p Value
a
 
Age (yrs) 43.9 ± 11.6 43.3 ± 10.2 46.0 ± 10.8 43.0 ± 12.3 0.444 
Male 67 (54.9) 12 (66.7) 22 (61.1) 33 (48.5) 0.262 
Caucasian 54 (45.0) 4 (22.2) 14 (38.9) 37 (54.4) 0.034 
Age at diagnosis (yrs) 25.2 ± 10.5 24.0 ± 12.1 27.0 ± 12.9 24.6 ± 8.5 0.479 
Diagnosis     0.170 
  Schizophrenia 41 (33.6) 6 (33.3) 14 (38.9) 21 (30.9)  
  Schizoaffective disorder 63 (51.6) 6 (33.3) 19 (52.8) 38 (55.9)  
  Psychotic disorder NOS 18 (14.8) 6 (33.3) 3 (8.3) 9 (13.2)  
Comorbid hyperlipidemia 
diagnosis 
39 (32.0) 9 (50.0) 12 (33.3) 18 (26.5) 0.172 
Use of statins 23 (18.9) 6 (33.3) 7 (19.4) 10 (14.7) 0.230 
Use of other lipid-lowering 
agent
11 (9.0) 
1
 
3 (16.7) 2 (5.6) 6 (8.8) 0.437 
Comorbid hypertension 
diagnosis 
47 (38.9) 9 (50.0) 17 (47.2) 21 (30.9) 0.148 
Use of ACEI or ARB 25 (20.5) 5 (27.8) 7 (19.4) 13 (19.1) 0.723 
Use of other antihypertensive 
drug 
33 (27.0) 2 (11.1) 14 (38.9) 17 (25.0) 0.081 
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Table 1. Demographic and Clinical Characteristics of the Study Patients by Education Subgroup 
Data are mean ± SD or no. (%) of patients. 
Low education = no high school completion or equivalent, moderate education = completion of high school or equivalent, and high education = any 
degree of post–high school education; NOS = not otherwise specified; ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II 
receptor blocker. 
aAnalysis of variance, χ2
 
, or the Fisher exact tests were used as appropriate to identify any significant differences in characteristics between the 
three education groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Use of atypical antipsychotic  
 
113 (92.6) 17 (94.4) 33 (91.7) 63 (92.6) 0.934 
Total activity score 2669 ± 2977 2520 ± 2775 3555± 3927 2239 ± 2320 0.097 
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Table 2. Genotype Risk Allele Carrier Status for All Patients by Education Subgroup 
 
Risk Allele Carrier Status 
All Patients 
(n=122) 
Low-Education Group 
(n=18) 
Moderate-Education 
Group (n=36) 
High-Education Group 
(n=68) 
p Value
a
 
APOE ε4 carrier 35 (28.9) 5 (27.8) 10 (28.6) 20 (29.4) 0.9891 
AGT M268T T carrier 89 (73.6) 13 (76.2) 29 (80.6) 47 (69.1) 0.434 
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ACE I/D D carrier 88 (72.7) 12 (70.6) 30 (83.3) 50 (67.7) 0.227 
Data are mean ± SD or no. (%) of patients. 
Low education = no high school completion or equivalent, moderate education = completion of high school or equivalent, and high education = any 
degree of post–high school education 
aSignificance assessments (χ2
 
) revealed no significant differences in the proportions of patients carrying the listed risk alleles among the three 
education subgroups. 
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Table 3. Results of the Linear Mixed-Effects Model Analysis: Verbal Memory Raw Scores in the Low-Education Group (n=18) 
 
      95% Confidence Interval 
Term Estimate SE DF t-ratio p value Lower Upper 
Fixed Effects        
Intercept 41.53 7.58 6.3 5.48 0.001 23.17 59.89 
APOE ε4 carrier -6.43 1.86 10.7 -3.47 0.006 -10.53 -2.34 
AGTrs699 C carrier 10.70 3.13 11 3.41 0.006 3.80 17.59 
ACE D carrier -4.41 1.58 10.3 -2.79 0.019 -7.92 -0.89 
Age -0.35 0.13 9.2 -2.71 0.024 -0.64 -0.06 
Random Effects        
Race 61.27 91.47    -118.02 240.55 
Residual 19.87 9.58    9.27 68.65 
SE = standard error, DF = degrees of freedom. 
 
 
 
Table 4. Results of the Linear Mixed-Effects Model Analysis: Recall Ratio Raw Scores in the Low-Education Group (n=18) 
 
      95% Confidence Interval 
Term Estimate SE DF t-ratio p value Lower Upper 
Fixed Effects        
Intercept 0.554 0.101 6.3 5.48 0.001 0.309 0.798 
APOE ε4 Carrier -0.086 0.025 10.8 -3.46 0.006 -0.140 -0.031 
AGT C carrier 0.143 0.042 11 3.41 0.006 0.050 0.235 
ACE D carrier -0.059 0.021 10.3 -2.78 0.019 -0.106 -0.012 
Age -0.005 0.002 9.2 -2.7 0.024 -0.009 -0.001 
Random Effects        
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Race 0.011 0.016    -0.021 0.043 
Residual 0.004 0.002    0.002 0.012 
SE = standard error, DF = degrees of freedom. 
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